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The 18 kDa translocator protein (TSPO) is involved in the immune/inflammatory
response. However, the exact role that TSPO plays in neuroinflammation-induced
cognitive impairment is still elusive. The purpose of our present study was to investigate
the effects of lentiviral-mediated hippocampal overexpression of the TSPO in a mouse
model of LPS-induced cognitive impairment. We established a mouse cognitive
impairment model using systematic daily administration of lipopolysaccharide (LPS)
(0.5 mg/kg). Microinjection of the dentate gyrus of the mouse with lentiviral vectors,
which contained a cDNA targeting TSPO (Lv-TSPO), resulted in a significant increase
in TSPO expression and allopregnanolone production. Mice treated with LPS showed
cognitive deficits in the novel object recognition test and the Morris water maze test
that could be ameliorated by TSPO overexpression. In addition, TSPO overexpression
reversed LPS-induced microglial activation and accumulation of pro-inflammatory
cytokines, including IL-1β, IL-6, and TNF-α. Moreover, TSPO overexpression attenuated
the LPS-induced impairment of hippocampal neurogenesis. Our results suggest that
local overexpression of TSPO in the hippocampal dentate gyrus alleviated LPS-induced
cognitive deficits, and its effects might be mediated by the attenuation of inflammatory
cytokines, inhibition of microglial activation, and promotion of neurogenesis.
Keywords: neuroinflammation, TSPO, cognitive impairment, allopregnanolone, neurogenesis, hippocampus
INTRODUCTION
Cognitive impairment, a common and serious symptom, deeply influences people’s quality of
life worldwide. Neuroinflammation plays pivotal roles in the neuropathogenesis of diseases
with cognitive impairment, such as Alzheimer’s disease (AD; Agostinho et al., 2010) and
postoperative cognitive dysfunction (POCD; Wan et al., 2007). In addition, drugs such as non-
steroidal anti-inflammatory drugs (NSAIDs) and proliferator-activated receptor gamma (PPARγ)
agonists suppress neuroinflammation and alleviate cognitive impairment in several animal models
(Steinman, 2010; Mandrekar-Colucci and Landreth, 2011; Shadfar et al., 2015). However, in clinical
Frontiers in Pharmacology | www.frontiersin.org 1 October 2016 | Volume 7 | Article 384
fphar-07-00384 October 18, 2016 Time: 10:32 # 2
Wang et al. TSPO Modulates Inflammatory Cognitive Impairment
trials, there have been disappointing outcomes when these drugs
were tested in patients with cognitive deficits (Breitner et al.,
2011; Geldmacher et al., 2011).
Allopregnanolone, one of the most important neurosteroids,
has been reported to attenuate neuroinflammation in several
animal models (Wang et al., 2010; Nezhadi et al., 2016).
Pre-clinical studies have demonstrated that decreased
allopregnanolone levels in the brain were associated with
neuroinflammatory cognitive deficits in rats (George et al.,
2010). Additionally, allopregnanolone administration induced
neuroprotective effects and attenuated neuroinflammatory
cognitive impairment in rodents (Wang et al., 2010;
Nezhadi et al., 2016). Interestingly, accumulating evidence
has revealed that the 18 kDa translocator protein (TSPO),
which represents the starting point and an important rate-
limiting step in neurosteroidogenesis, plays an important role
during neuroinflammation (Chen and Guilarte, 2008). It was
reported that the level of TSPO was increased during the
neuroinflammatory process, while TSPO ligands exerted anti-
inflammatory and neuroprotective effects in vivo and in vitro
by increasing the production of allopregnanolone. For example,
TSPO ligands decreased the expression of pro-inflammatory
cytokines in BV-2 cells exposed to lipopolysaccharide (LPS)
(Karlstetter et al., 2014), dampened pro-inflammatory microglial
reactivity in the retina (Scholz et al., 2015), attenuated pathology
in a mouse model of Alzheimer’s disease (Barron et al., 2013), and
even reversed the cognitive impairment induced by LPS in mice
(Ma et al., 2016). Thus far, TSPO ligands have been developed
as potential molecular markers to detect neuroinflammation
and have been applied in the assessment of neuroinflammation
in patients with several neuropathological conditions that
are accompanied by cognitive impairment (Batarseh and
Papadopoulos, 2010; Colasanti et al., 2014; Rissanen et al.,
2014; Suridjan et al., 2015; Zurcher et al., 2015; Wang et al.,
2016). These interesting data gave reason to hypothesize that
downregulation of TSPO in the brain could be a risk factor for
the etiology of neuroinflammatory cognitive impairment, and
increased TSPO might be a novel pharmacological treatment
strategy for cognitive impairment.
Although TSPO ligands exert anti-inflammatory and
neuroprotective effects in vivo, as described above, we
cannot exclude the systemic effects of TSPO ligands during
neuroinflammation because TSPO is expressed at a high level
in the testis, adrenal cortical, ovarian granulose, and luteal
cells, as well as in the placenta brain glial cells (Papadopoulos
et al., 2006). The hippocampus, an important area mediating
the learning and memory process, has been implicated in the
pathophysiology of many diseases associated with cognitive
impairment (Biessels and Reagan, 2015; Dietrich et al., 2015).
On the other hand, hippocampal neurogenesis, which can be
suppressed by neuroinflammation, is closely related to cognitive
performance (Chesnokova et al., 2016). Studies have also
revealed that hippocampal TSPO expression is increased in
systemic lupus erythematosus patients with neuroinflammatory
cognitive impairment (Wang et al., 2016). However, the exact
molecular and cellular mechanism of hippocampal TSPO in
neuroinflammation remains unclear.
Based on the aforementioned factors, in the present study,
we used a lentivirus to overexpress the TSPO protein in
the hippocampal dentate gyrus. We first investigated whether
overexpression of TSPO could reverse the cognitive impairment
induced by LPS. Then, we investigated pro-inflammatory
cytokines and microglial activation of the hippocampus.
Furthermore, we examined hippocampal neurogenesis after
hippocampal TSPO overexpression. The results obtained in this
study provided new insights into the potential mechanisms and
targets for the treatment of inflammatory cognitive impairment.
MATERIALS AND METHODS
Animals
Male ICR mice (22 to 26 g) were obtained from the Beijing SPF
Animal Technology Company (Beijing, China). All animals were
housed in a temperature-controlled animal facility with a 12-h
light-dark cycle (lights on at 6:00 AM) and had full access to
water and food ad libitum. Animal experiments were performed
in compliance with the current laws of China and the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals (NIH publication No. 86–23, revised 1996).
Plasmid Construction
Recombinant pGC-LV-GV287-EGFP vectors with the TSPO
(NM_009775) gene (LV-TSPO) or with a scrambled control
sequence (negative control, NC) were constructed by the
Genechem Company (Genechem Co. Ltd, Shanghai, China). All
the viral vectors contained EGFP as a marker to track lentivirus-
mediated target gene expression by fluorescence microscopy.
Preparation of Lentiviral Stocks
The viral particles were produced by transient transfection of
HEK 293T cells with a transfer plasmid. In brief, the pGC-
LV-GV287-EGFP-TSPO/NC vectors, mixed with pHelper1.0
and pHelper2.0, were co-transfected into HEK-293T cells with
LipofectamineTM 2000 (Invitrogen, Shanghai, China) according
to the manufacturer’s instructions. Forty-eight hours after
transfection, the viral supernatants were collected, filtered
through 0.45 µm polyvinylidene fluoride membranes, and then
centrifuged. To ensure comparability among different virus
preparations, the virus concentration was determined by real-
time RT-PCR to measure the number of integrated copies of 293T
cells and was reported as transducing units (2× 108 tu/ml). After
transduction, the vectors were re-suspended in 10% sucrose/PBS
and stored at−80◦C.
Experimental Design
Bromodeoxyuridine (Brdu) and LPS (Escherichia coli EH100)
were purchased from Sigma–Aldrich (St. Louis, MO, USA). Both
were dissolved in saline and administered by intraperitoneal
injection (i.p.) in a volume of 10 ml/kg. First, we explored the
optimal dose of LPS (0.2, 0.5, and 1 mg/kg, i.p.) that did not
affect locomotor activity following consecutive administrations
for 6 days (Figure 1A). The open field test (OFT) was conducted
12, 16, 20, and 24 h after each injection (days 1–6).
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FIGURE 1 | Experimental design. (A) Treatment schedule and test order for the optimized dose of lipopolysaccharide (LPS). LPS or saline was administered
consecutively for 6 days following a 1-week acclimatization. The open field test (OFT) was performed 12, 16, 20, and 24 h after LPS/saline administration over the
subsequent 6 days. (B) Treatment schedule and test order for evaluating the effects of TSPO overexpression and LPS. Brdu was injected three times at 3-h intervals.
The next day, lentiviral vectors containing TSPO-cDNA (Lv-TSPO) or the negative control (NC) sequence were infused into the bilateral dentate gyrus (2 × 108 tu,
1 µl/side) of the mouse hippocampus. Behavioral tests were carried out from day 15 to day 26. LPS (0.5 mg/kg) or saline was injected (i.p.) once daily from day 14
to day 26, and the animals were sacrificed on day 27. MWM, Morris water maze; OFT, open field test; NOR, novel object recognition; LV, lentiviral vectors; SAC,
sacrifice.
In the next phase, the mice were divided into four groups:
negative control (NC)+ saline; NC+ LPS; Lv-TSPO+ saline; Lv-
TSPO + LPS. One day before virus injection, Brdu (100 mg/kg)
was injected (i.p.) three times at 3 h intervals. On day 0,
the Lv-TSPO or NC virus was microinjected into the bilateral
dorsal dentate gyrus. Briefly, mice were anesthetized with chloral
hydrate (400 mg/kg, Sinopharm Chemical Reagent Co., Ltd,
Shanghai, China) before they were placed in a stereotaxic holder
(Kopf Instruments, Tujunga, CA, USA). A 33-gage Hamilton
microsyringe was inserted into the dorsal dentate gyrus (AP, -
1.7 mm from the bregma; ML, ±1.8 mm from the midline;
DV, −2.0 mm from the dura) on each side. Lentiviral vectors
(1 µl/side) containing cDNA targeting TSPO or the NC were
infused at a rate of 0.2 µl/min using a UMP3 microsyringe
injector and a Micro4 controller (World Precision Instruments,
Sarasota, FL, USA). The needle was slowly retracted after an
additional 5 min to assure adequate diffusion of the vectors.
From day 14 to day 26, LPS or saline was administered daily
by intraperitoneal injection. Behavior tests were conducted 20 to
24 h after each injection of LPS or saline (Figure 1B).
Behavioral Experiments
Open Field Test (OFT)
Mice were placed in the corner of a plastic box
(60 cm × 60 cm × 23 cm) in which the base was divided
into 16 equal sectors; after a 5-min acclimation period, the
number of crossings (with all four paws placed into a new
square) and rearings (raising the forepaws) were recorded over
the next 5 min. The open field box was cleaned with 5% ethyl
alcohol to hide animal clues.
Novel Object Recognition (NOR) Test
The NOR test was carried out in a dimly lit room. During the
habituation session, the mice were allowed to become familiar
with the testing box for 5 min on day 15. Twenty-four hours later,
the mice were placed in the same apparatus and were individually
exposed to two identical objects placed in two corners of the box
for 5 min (the sample session). After another 24 h interval (on day
17), the mice were returned to the box with a previously presented
familiar object and a novel one for 5 min (the test session).
Exploration was defined as initiatively facing, sniffing or touching
the object (within 2 cm from the object). The accumulative time
exploring each object (Tf and Tn for familiar and novel objects,
respectively) was recorded to determine the recognition index
[RI= Tn/(Tn+ Tf)].
Morris Water Maze (MWM) Test
The MWM test was performed as described previously with
minor modifications (Vorhees and Williams, 2006). Behavioral
testing was conducted in a circular pool (122 cm diameter, 35 cm
depth), which was divided into four equally spaced quadrants.
The pool was filled to a depth of 17 cm with water (21 ± 1◦C)
made opaque by the addition of powdered milk. A circular
platform (10 cm2) was placed in the center of one of the quadrants
1.5 cm below the surface of the water. The pool was located in
a well-lit room with some external cues, which remained in the
same location throughout the acquisition and the probe trials.
On day 20, the mice were individually placed in the pool facing
the wall four times (1 min each time and each time starting in a
different quadrant) without the platform to become accustomed
to the pool. From day 21 to day 25, the mice were individually
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placed in the pool at different starting points, except for the target
quadrant containing the hidden platform. The animals were
trained to escape by swimming and climbing onto the platform
during the acquisition trials (4 trials × 5 days, 20 trials in total).
The mice that failed to find the hidden platform within 60 s were
guided toward it and stayed there for 10 s before being removed.
The latency to escape by swimming onto the platform was
recorded. Twenty-four hours after the last acquisition training
trial, the probe trial was conducted in the absence of the platform.
The number of entries and the time spent in the target quadrant
were recorded, with a cut-off time of 60 s.
Enzyme-Linked Immunosorbent Assay (ELISA)
Concentrations of IL-1β (Biosource, Invitrogen, USA), TNF-α
(Biosource, Invitrogen, USA), IL-6 (Biosource, Invitrogen, USA)
and allopregnanolone (Arbor Assays, Ann Arbor, MI, USA) were
examined by ELISA following the manufacturers’ instructions.
Hippocampal tissues of 3 mm in diameter around the injection
site were punched out. Then, the tissues were homogenized in
RIPA lysis buffer (Applygen, China) on ice. Supernatant protein
concentrations were determined with a BCA protein assay kit
(Pierce, USA) after centrifugation at 12,000 g for 15 min. The
absorbance was read on a spectrophotometer at a wavelength of
450 nm and a reference wavelength of 650 nm.
Western Blot Analysis
The punched hippocampal tissues (3 mm in diameter around the
injection sites on both sides) were extracted by RIPA lysis buffer
(Applygen, China) plus protease inhibitor and phosphatase
inhibitor cocktail (Thermo Pierce, Rockford, IL, USA). Equal
amounts (50 µg) of protein were resolved by electrophoresis,
transferred onto polyvinylidene difluoride (PVDF) membranes
and blocked with 5% skim milk solution. The membranes were
incubated with rabbit anti-TSPO (at a dilution of 1:1000; Abcam,
Cambridge, MA), or β-actin (1:3000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 4◦C overnight. After washing and
incubating with secondary antibodies (1:3000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), the specific bands were
detected and quantified using Gel-Pro Analyzer software, Version
3.1 (Media Cybernetics, Bethesda, MD, USA).
Immunohistochemistry
Immunohistochemistry was performed as described in our
previous report (Li et al., 2009) and as described by Zhang
et al. (2015). In brief, free-floating brain sections were incubated
for 1 day in cold PBS-plus containing rat anti-Brdu (1:200;
Abcam, Cambridge, MA, USA) and mouse anti-NeuN (1:1000;
Chemicon, Temecula, CA, USA), or rabbit anti-Iba1 (1:200;
Jackson, MS, USA). After rinsing with PBS, the sections were
incubated with Red-X-conjugated goat anti-rat IgG and FITC-
conjugated goat anti-mouse IgG, or FITC-conjugated anti-
rabbit IgG (both at a dilution of 1:200; Jackson, MS, USA) in
PBS for 2 h. After rinsing, the sections were then mounted
with Vectashield medium for fluorescence imaging (Vector
Laboratories, Burlingame, CA, USA). Fluorescence analyses were
performed using confocal laser microscopy.
To determine the percentage of newborn neurons among
the Brdu-labeled cells, at least fifty Brdu-positive cells in the
dentate gyrus were randomly identified in each animal, for which
the number of cells in each category was determined. Brdu-
positive cells were counted using a modified stereology protocol
(Li et al., 2009). For Iba1, a marker of activated microglia,
we followed Zhang’s methods (Zhang et al., 2015). Every sixth
section throughout the entire hippocampus was processed for
Brdu/NeuN or Iba1 immunohistochemistry. All Brdu-labeled
and Iba1-labeled cells in the granular cell layer and hilus were
counted blindly through a 60× objective to distinguish individual
cells. The number of counted cells was multiplied by six and
was recorded as the total number of labeled cells in the dentate
gyrus. Images were captured using a Leica TCS SP5 confocal
imaging system. Integral optical density (IOD) for Iba1 staining
was quantified using Image-Pro Plus 6.0 software.
Statistical Analysis
All data were analyzed by an observer who was blind
to the experimental protocol. The data are expressed as
the means ± standard error (SEM) and analyzed with the
statistical analysis software GraphPad Prism, Version 6.0
(GraphPad, San Diego, CA, USA). Two-group comparisons were
analyzed by a two-tailed Student’s t-test. Comparisons between
multiple groups were carried out using two-way ANOVA
with Bonferroni’s multiple comparisons post hoc test where
appropriate. For acquisition training and spatial memory testing
in the MWM task, the data were analyzed using two-way ANOVA
(treatment × trial time) with repeated measures (trial days).
P < 0.05 was considered statistically significant.
RESULTS
Optimal Dose of LPS and Administration
Time
To optimize the dose of LPS without alteration of locomotor
activity, three different doses of LPS were chosen for 6 days
of daily intraperitoneal injection. LPS (0.2, 0.5 and 1 mg/kg)
significantly decreased line crossing and rears 12 h and 16
after intraperitoneal injection in the OFT (P < 0.05, n = 6;
Figures 2A,B). After 20 h, the mice that received 0.2 or
0.5 mg/kg LPS showed no difference in line crossing or rears
compared with control mice. Only mice that received 1 mg/kg
LPS exhibited decreased locomotor activity compared with
control mice (P < 0.05). In the following 5-day tests, the mice
showed results similar to those of the 1st day (data not shown).
To induce significant neuroinflammation without affecting the
locomotor activity, we chose 0.5 mg/kg LPS in the subsequent
tests.
Lv-TSPO Increased TSPO Expression
and Allopregnanolone Level in the
Hippocampus
The experiment was designed for determining the effect of
overexpression of TSPO mediated by lentivirus. Fourteen days
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FIGURE 2 | Locomotor activity after administration of different doses of LPS. The open field test was conducted at different times after the first LPS injection.
(A) Line crossing times in the OFT. (B) Rears in the OFT. LPS (0.2, 0.5, and 1 mg/kg) decreased locomotor activity 12 and 16 h after injection, but it recovered after
20 h, except in the 1 mg/kg mice (n = 6). ∗P < 0.05, ∗∗∗P < 0.001 vs. saline group.
after microinjection, the mice were sacrificed for analysis.
We traced high and specific expression of EGFP, which was
encoded in the sequence of the lentivirus, in the dentate
gyrus (Figure 3A). Lv-TSPO increased TSPO expression
(3 mm in diameter around the injection site on both sides)
approximately fourfold compared with that in NC mice
(P< 0.001; Figure 3B). The allopregnanolone level in the dentate
gyrus was significantly increased after TSPO overexpression
(P < 0.05, Figure 3C). Collectively, our results suggest that
Lv-TSPO mediated the successful overexpression of TSPO in
the dentate gyrus, which elevated the allopregnanolone level
significantly.
Lv-TSPO Ameliorates Cognitive
Impairment Induced by LPS
Fourteen days after microinjection of the Lv-TSPO or NC vectors,
0.5 mg/kg of LPS or saline was injected intraperitoneally daily.
The OFT was conducted before the other behavior tests. Both
Lv-TSPO and LPS had no effect on line crossing (P > 0.05,
Figure 4A) or rears (P > 0.05, Figure 4B).
Repeated-measures two-way ANOVA revealed that swimming
speed during the 6 days of the MWM was not affected by LPS or
Lv-TSPO (Ftreatment = 0.4749, P= 0.7017; Figure 4C). The escape
latency improved over time while the acquisition process seemed
not to be affected by LPS and Lv-TSPO (Ftime= 65.94, P< 0.0001,
Ftreatment = 2.408, P = 0.0687; Figure 4D). Interestingly, LPS
decreased the crossing times and the time percentage in the
target quadrant. Additionally, Lv-TSPO reversed the reduction
in the probe trial (FLPS = 6.23, P = 0.0173, FLv−TSPO = 4.225,
P = 0.0471, FLv−TSPO × LPS = 3.643, P = 0.0643 for crossing
time; FLPS = 6.952, P = 0.0123, FLv−TSPO = 1.961, P = 0.1699,
FLv−TSPO×LPS = 7, P = 0.012 for target quadrant; Figures 4E,F).
Bonferroni’s multiple comparison showed that NC + LPS mice
had less platform crossing times than the NC + saline mice
(P < 0.01) and Lv-TSPO + LPS mice (P < 0.05), and they also
spent less time in the target quadrant than the NC + saline mice
(P < 0.01) and Lv-TSPO+ LPS mice (P < 0.05).
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FIGURE 3 | Lv-TSPO increased TSPO expression and allopregnanolone levels in the hippocampus. (A) Microinjection of Lv-TSPO induced high, specific
expression of EGFP (green) in the dentate gyrus, as observed under fluorescence microscopy. Scale bar = 200 µm. (B) Lv-TSPO increased hippocampal TSPO
expression significantly. Protein bands on the gel, and the expression level was normalized to β-actin as an internal control. Values are expressed as fold-change
over the mean values of the negative control mice. (C) Lv-TSPO significantly increased allopregnanolone expression. The data are expressed as the means ± SEM
(n = 6). ∗∗∗P < 0.001 vs. NC.
In the NOR test, LPS-induced cognitive impairment was
shown as the reduction of the recognition object index. Lv-TSPO
could ameliorate this impairment (FLPS = 4.755, P = 0.0358,
FLv−TSPO = 1.704, P = 0.2001, FLv−TSPO×LPS = 7.052,
P= 0.0117; Figure 4G). Our data suggested that the LPS-induced
cognitive impairment could be reversed by TSPO overexpression
in the dentate gyrus.
Lv-TSPO Suppresses LPS-Induced
Microglial Activation and Accumulation
of Inflammatory Cytokines in the
Hippocampus
In view of the important roles that microglial activation
plays in inflammatory cognitive impairment (Annane and
Sharshar, 2015), we investigated the expression of the Iba1
protein in the dentate gyrus (Figure 5A). Our results showed
that LPS clearly caused microglial activation while Lv-TSPO
suppressed microglial activation (FLPS = 28.30, P = 0.0002,
FLv−TSPO = 5.520, P= 0.0367, FLv−TSPO×LPS = 5.314, P= 0.0398
for number; FLPS = 24.63, P = 0.0003, FLv−TSPO = 9.275,
P = 0.0102, FLv−TSPO×LPS = 5.911, P = 0.0317 for density;
Figures 5B,C).
We also investigated the levels of several pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-α) in the
hippocampus. An ELISA assay showed that LPS caused
obvious increases in IL-1β (FLPS = 14.28, P = 0.0012,
Figure 5D), IL-6 (FLPS = 66.04, P < 0.0001, Figure 5E)
and TNF-α (FLPS = 38.26, P < 0.0001, Figure 5F).
Lv-TSPO reversed the LPS-induced accumulation of pro-
inflammatory cytokines (FLv−TSPO = 5.916, P = 0.0245,
FLv−TSPO×LPS = 1.663, P= 0.2119; FLv−TSPO = 22.9, P= 0.0001,
FLv−TSPO×LPS = 24.19, P < 0.0001; FLv−TSPO = 9.186,
P = 0.0066, FLv−TSPO×LPS = 2.011, P = 0.1716; for IL-1β,
IL-6, and TNF-α, respectively). These data indicated that
TSPO overexpression partially reversed the accumulation
of pro-inflammatory cytokines and microglial activation in
hippocampus induced by LPS.
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FIGURE 4 | Lv-TSPO ameliorates cognitive impairment in LPS-exposed mice. All behavioral tests were performed as described in the Methods section. Both
LPS and Lv-TSPO have no effect on spontaneous locomotor activity, as tested by the open field test. (A) Line crossing times in the OFT. (B) Rears in the OFT.
(C) Swimming speed showed no difference among groups during the MWM test. (D) Escape latency during the acquisition training process showed no difference at
each time point among all the groups. (E,F) LPS decreased the time for platform crossing and the percentage of target quadrant occupancy during time in the probe
trial. The reduction was reversed by Lv-TSPO. (G) LPS decreased the index of recognition in the NOR test, while Lv-TSPO could reverse this reduction. The data are
expressed as the means ± SEM (n = 10). ∗P < 0.05, ∗∗P < 0.01 vs. NC + saline, #P < 0.05 vs. NC + LPS. MWM, Morris water maze; OFT, open field test; NOR,
novel object recognition; Lv, lentiviral vectors.
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FIGURE 5 | Lv-TSPO suppresses the LPS-induced accumulation of inflammatory cytokines and microglial activation in the hippocampus.
(A) Representative images of Iba1-labeled activated microglia in the hippocampal dentate gyrus. Activated microglia are shown in green. Scale bar = 150 µm.
(B) Quantification of the Iba1-labeled cells. LPS increased Iba1-labeled cells, while Lv-TSPO attenuated this increase. (C) LPS increased the integral optical density
(IOD) of Iba1 staining, which was attenuated by Lv-TSPO. The data are expressed as the means ± SEM (n = 4). LPS increased the accumulation of IL-1β (D), IL-6
(E) and TNF-α (F), all of which were reversed by Lv-TSPO. The data are expressed as the means ± SEM (n = 6). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs.
NC + saline, #P < 0.05, ###P < 0.001 vs. NC + LPS, &P < 0.05 vs. Lv-TSPO + saline.
Lv-TSPO Ameliorates the Reduction of
Neurogenesis Caused by LPS
Given that neurogenesis could be reduced by inflammation and
that this reduction might be linked with cognitive impairment
(Kohman and Rhodes, 2013; Chesnokova et al., 2016), we
labeled Brdu- and NeuN-positive cells in the dentate gyrus
by immunofluorescent means (Figures 6A,B). LPS reduced
not only the number of Brdu-positive cells (FLPS = 12.22,
P = 0.0044, Figure 6C) but also the number of cells co-labeled
with Brdu and NeuN (FLPS = 15.66, P = 0.0019, Figure 6D),
as well as the percentage of co-labeled cells of total Brdu-
positive cells (FLPS = 11.79, P = 0.0049, Figure 6E). Lv-TSPO
reversed this reduction at different levels (FLv−TSPO = 7.128,
P = 0.0204, FLv−TSPO×LPS = 6.056, P = 0.03 for Brdu+
cells; FLv−TSPO = 4.951, P = 0.046, FLv−TSPO×LPS = 7.369,
P= 0.018 for Brdu+/NeuN+ cells; FLv−TSPO = 4.406, P= 0.0576,
FLv−TSPO×LPS = 6.194, P = 0.0285, for the percentage
of new neurons in Brdu+ cells). These data indicate that
TSPO overexpression attenuated the impaired hippocampal
neurogenesis induced by LPS.
DISCUSSION
The present study demonstrated that overexpression of TSPO
in the hippocampal dentate gyrus significantly suppressed the
cognitive impairment induced by LPS in mice and that this
effect might be mediated by the attenuation of inflammatory
cytokines, inhibition of microglial activation, and promotion of
neurogenesis.
Systemic LPS administration can cause blood-brain
barrier disruption and neuroinflammation through a series
of mechanisms, inducing cognitive decline (Weintraub et al.,
2013). However, the method of LPS administration changed
from single to consecutive, and the dose applied to induce
cognitive dysfunction varied from 0.125 to 1 mg/kg (Wang
et al., 2013; An et al., 2015; Sun et al., 2015; Thangarajan
et al., 2015). Additionally, LPS-induced low locomotor activity
may have had an influence on the behavioral tests. It has also
been reported that following seven consecutive days of LPS
(0.25 mg/kg) administration, locomotor activity returned to
normal levels (Kahn et al., 2012). In the present study, we
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FIGURE 6 | Lv-TSPO ameliorates the reduction of neurogenesis caused by LPS. (A) Micrographs and quantification of Brdu-labeled cells (red) in the dentate
gyrus. Scale bar = 200 µm. (B) Confocal micrographs and quantification of NeuN (green) and Brdu (red) co-labeled cells in the dentate gyrus. Scale bar = 50 µm
(C) Brdu-labeled cells were decreased by LPS, which was reversed by Lv-TSPO. (D) LPS decreased the number of NeuN- and Brdu- co-labeled cells, which was
reversed by Lv-TSPO. (E) The percentage of new neurons among the Brdu-labeled cells was decreased by LPS, while this was attenuated by Lv-TSPO. The data
are expressed as the means ± SEM (n = 4). ∗∗P < 0.01 vs. NC + saline, #P < 0.05 vs. NC + LPS.
intended to investigate the cognitive performance of mice
beginning 1 day after the first LPS administration. Thus, we
optimized the dose and time of LPS administration so as to
not affect locomotor activity at first. We chose three doses of
LPS (0.2, 0.5, and 1 mg/kg, i.p. once a day for 6 days) based
on previous reports (Wang et al., 2013; An et al., 2015; Sun
et al., 2015; Thangarajan et al., 2015). Our data showed that
locomotor activity recovered after 20 h except in the 1 mg/kg
mice. Therefore, 0.5 mg/kg LPS (i.p. daily) was chosen, and the
subsequent behavioral tests were carried out 20 to 24 h after LPS
administration.
Translocator protein is expressed widely in different organs
of the body, including the testis, the adrenal cortex, ovarian
granulose and luteal cells, the placenta and brain glial
cells (Papadopoulos et al., 2006). To exclude the systemic
effects of TSPO ligands, we overexpressed TSPO in the
bilateral hippocampus using a lentivirus, which mediates
specific protein overexpression that can last for months
(Krassnig et al., 2015; Chen et al., 2016). As a marker,
EGFP is often applied to trace the location of lentiviral-
mediated protein overexpression (Eerola et al., 2014). In
the present study, the specific expression of EGFP (green)
was observed in the dentate gyrus after intra-hippocampal
injection of the Lv-TSPO, indicating that the method of local
overexpression was reliable. Western blot also suggested the
successful fusion of the TSPO gene by lentiviruses. All of
these data suggested that TSPO was highly expressed in the
DG of the hippocampus after intra-hippocampal injection
of Lv-TSPO. As the lentiviral vector stimulated hippocampal
TSPO signaling efficiently, we then examined whether this
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molecular change modified cognitive performance in an LPS-
induced cognitive impairment model. Cognitive performance
was evaluated by MWM and NOR, two robust and reliable
tests that are strongly correlated with hippocampal-dependent
memory (Vorhees and Williams, 2006; Li et al., 2011) that are
widely used in evaluating cognitive deficits induced by LPS
(Vorhees and Williams, 2006; Belarbi et al., 2012; Dong et al.,
2013; Fruhauf et al., 2015; Zhang et al., 2015). In our present
study, LPS induced clear cognitive deficits, exhibited as a decrease
in the recognition index in NOR and a decrease in platform
crossing and target quadrant occupancy during the MWM. All
of these behavioral changes were reversed by hippocampal TSPO
overexpression. Our present results are consistent with other
reports that found that TSPO ligands (PK11195) exhibited pro-
cognition effects in an LPS-induced cognitive impairment model
(Ma et al., 2016), while the possible mechanisms are worthy of
further investigation.
In an effort to better understand the anti-cognitive-
impairment effect of hippocampal overexpression of TSPO, we
then tested the possible mechanisms. Evidence has suggested
that the inflammatory process in the CNS is characterized by
microglial activation and the accumulation of pro-inflammatory
cytokines. In the event of brain insults, such as inflammation
and neurodegeneration, microglia activate by undergoing
morphological transformation from a “ramified” resting state
to an active, motile “amoeboid” state (Fields et al., 2014). It
is also reported that microglial activation is closely related to
LPS-induced cognitive impairment (Fields et al., 2014). Iba1 is
a 17 kDa protein that is specifically expressed in macrophages
and microglia. An increase in the IOD for Iba1 staining was
interpreted to signify microglial activation. Consistent with
previous reports, which revealed that TSPO ligands suppressed
microglial activation (Zhao et al., 2011; Bae et al., 2014; Karlstetter
et al., 2014). In the present study, TSPO overexpression in
the dentate gyrus reversed the number and density of Iba1-
labeled cells, indicating that TSPO overexpression suppressed
LPS-induced hippocampal microglial activation.
Microglial activation stimulates the accumulation of pro-
inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, which
are responsible for memory impairment induced by LPS (Van
Dam et al., 1995; Smith et al., 2012; Skelly et al., 2013). Previous
studies suggested that the overexpression of TSPO ameliorates
the LPS-induced accumulation of pro-inflammatory cytokines in
BV2 cells, while TSPO knock-down produced the opposite effect
(Bae et al., 2014). Moreover, numerous TSPO ligands (XBD173,
vinpocetine, RO5-4864) could attenuate microglial activation and
the accumulation of pro-inflammatory cytokines in vitro and
in vivo (Zhao et al., 2011; Bae et al., 2014; Karlstetter et al.,
2014). Consistent with these findings, we demonstrated that LPS
increased the production of IL-1β, IL-6 and TNF-α, which was
reversed by TSPO overexpression and is also consistent with
behavioral tests.
Studies have demonstrated that adult hippocampal
neurogenesis plays a major role in learning and memory, and
impairment of hippocampal neurogenesis leads to cognitive
deficits (van Praag et al., 2002; Lazarov and Marr, 2010; Ekdahl,
2012). In addition, hippocampal neurogenesis was suppressed by
many factors, such as microglial activation and pro-inflammatory
cytokines (van Praag et al., 2002; Green et al., 2012; Ekdahl,
2012; Chesnokova et al., 2016). Our present study found that
overexpression of TSPO suppressed microglial activation and
the accumulation of pro-inflammatory cytokines in the DG
of the hippocampus. Allopregnanolone, which is promoted
by TSPO overexpression, might modulate neurogenesis in
rodents (Brinton and Wang, 2006; Charalampopoulos et al.,
2008). Therefore, we hypothesized that Lv-TSPO and the
subsequent synthesis of allopregnanolone targeting adult
neurogenesis may be beneficial for the improvement of
cognitive impairment. To address our hypothesis, we next
investigated the effect of hippocampal TSPO overexpression
on hippocampal neurogenesis. We found that chronic
treatment with LPS decreased hippocampal neurogenesis,
while hippocampal TSPO overexpression reversed the impaired
hippocampal neurogenesis, which was consistent with previous
reports that revealed that anti-inflammatory drugs, as well as
allopregnanolone, promoted neurogenesis in animal models
(Brinton and Wang, 2006; Charalampopoulos et al., 2008;
Varnum et al., 2015; Vay et al., 2016). Thus, we considered
that the reversal of the impaired neurogenesis induced by
LPS contributed to the neuroprotective effects of TSPO
overexpression.
CONCLUSION
To our knowledge, this is the first report of the mechanisms of
lentiviral-mediated TSPO overexpression in the dentate gyrus
against neuroinflammatory cognitive impairment. It should also
be stated that in the present study, we did not antagonize the
effect of allopregnanolone. Therefore, we could not completely
attribute the anti-inflammatory effects of TSPO overexpression to
allopregnanolone. Nevertheless, the results of these investigations
advanced our knowledge of TSPO during neuroinflammatory
cognitive dysfunction, which is a potential therapeutic target for
the treatment of inflammatory cognitive deficits.
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